Cough in IPF Studies: Why Does it Count?
Idiopathic pulmonary fibrosis (IPF) presents a unique set of considerations for lung function assessment in clinical trials, including understanding the significance of monitoring cough as an endpoint.
Don’t miss the opportunity to see this webinar from Steven D. Nathan MD, who will share valuable insights into IPF study design including cough. This webinar is relevant to anyone interested in clinical trials with a respiratory focus, or those working in the area of chronic cough, IPF or ILD.
Objectives
- Overview of IPF and other ILDs
- Significance and clinical relevance of cough in IPF
- Cough assessment in clinical practice
- Cough as an endpoint in IPF drug trials
- Challenges in assessing cough in clinical trials
This webinar was originally broadcast on Thursday 11 April 2024. View the webinar on demand in the player below.